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Background. Diabetic kidney disease is the leading cause of end-stage renal failure despite intensive treatment of modifiable risk
factors. Identification of new drug targets is therefore of paramount importance.The complement system is emerging as a potential
new target. The lectin pathway of the complement system, initiated by the carbohydrate-recognition molecule mannan-binding
lectin (MBL), is linked to poor kidney prognosis in diabetes. We hypothesized that MBL activates complement upon binding
within the diabetic glomerulus.Methods.We investigated this by comparing complement deposition and activation in kidneys from
streptozotocin-induced diabetic mice and healthy control mice. Results. After 20 weeks of diabetes, glomerular deposition of MBL
was significantly increased. Diabetic animals had 2.0-fold higher (95% CI 1.6–2.5) immunofluorescence intensity from anti-MBL
antibodies compared with controls (𝑃 < 0.001). Diabetes and control groups did not differ in glomerular immunofluorescence
intensity obtained by antibodies against complement factors C4, C3, and C9. However, the circulating complement activation
product C3a was increased in diabetes as compared to control mice (𝑃 = 0.04). Conclusion. 20 weeks of diabetes increased MBL
autoreactivity in the kidney and circulating C3a concentration. Together with previous findings, these results indicate direct effects
of MBL within the kidney in diabetes.
1. Introduction
Diabetic kidney disease affects about 30% of patients with
diabetes, causing impaired quality of life and putting signif-
icant strain on health care systems worldwide [1]. Despite
intensive treatment of risk factors such as blood glucose and
blood pressure, diabetic nephropathy remains the primary
cause of end-stage renal failure which requires transplanta-
tion or dialysis [2, 3]. Persistent research to identify novel
therapeutic targets is therefore of paramount importance.
The lectin pathway of complement activation is emerging
as a potential drug target. Clinical observations through the
last decade link the complement-activating carbohydrate-
recognizing molecule mannan-binding lectin (MBL) to dia-
betic kidney disease [4–9]. In addition, we have recently
described that the concentration-determiningMBL genotype
is tightly associated with mortality in type 1 diabetes patients
[10]. Animal studies indicate a causal role ofMBL in this asso-
ciation asMBL knockoutmice are resistant to diabetic kidney
changes [11, 12]. In vitro studies suggest that diabetes-induced
glycoprotein alterations may adversely activate complement
through binding of MBL to neoepitopes [13, 14]. These
diabetes-induced neoepitopes may develop through either
altered enzymatic protein glycosylation or nonenzymatic
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formation of advanced glycation end-products [15–17]. By use
of plant lectins selective for specific carbohydrate patterns,
it has been shown that diabetes alters the carbohydrate
composition in tissues [18, 19]. Furthermore, diabetic kidney
tissue has increased reactivity with the lectin concanavalin
A which binds mannose [20]. Diabetes-induced deposition
of complement factor C3 as a sign of complement attack has
been demonstrated in rats [21–23]. In addition, complement
regulatory proteins are inhibited by nonenzymatic glycation
in diabetes which leads to accelerated complement attack
[24, 25]. The ensuing sublytic effects induce a mitogen
stimulus and growth factor release, which further links
the complement system mechanistically to diabetic kidney
changes [26, 27].
The specific contribution of the lectin pathway to the
complement activation remains unknown, and no studies
have investigated the autoreactivity of MBL in the kidney
in diabetes. We hypothesize that MBL is deposited within
the diabetic glomerulus as a consequence of binding to
hyperglycemia-induced neoepitopes and that this initiates
complement activation contributing to diabetic kidney dam-
age. To test this hypothesis, we examined MBL deposition
within the diabetic glomerulus andmeasured glomerular and
circulating complement components.
2. Materials and Methods
2.1. Animals. Six-week-old C57BL/6JBomTac male mice
(Taconic, Ry, Denmark) were randomized to a control group
(𝑛 = 12) or a diabetes group (𝑛 = 20). At eight weeks of age,
experimental type 1 diabetes was induced by streptozotocin.
For five consecutive days, the animals in both groups were
fasted for four to six h prior to injection with either the empty
buffer in control group or low-dose streptozotocin (55mg/kg,
catalogue number (Ca) S0130 Sigma-Aldrich, St. Louis, MO,
USA) dissolved in cold 10mmol/L citrate acid buffer, pH
4.5, in the diabetes group [28]. For the remaining time, all
animals had free access to standard chow (Altromin 1324,
Lage, Germany) and tap water. Animals were housed as litter
mates, two to eight per cage, in a room with an artificial light
circle (light 6.00 a.m. to 6.00 p.m.), temperature at 21 ± 1∘C,
and 55 ± 5% humidity. The study complied with the Danish
regulations for care and use of laboratory animals (license
number 2012-15-2934-00113 of July 5, 2012).
Blood glucose was monitored throughout the study on
tail-vein blood by Contou™ (Bayer Diabetes Care, Kongens
Lyngby, Denmark). If blood glucose was above the limit of
quantification (33.3mmol/L), the missing value was replaced
by 33.4mmol/L in statistical evaluations.
During the study and prior to quantification of any
outcomemeasurements, seven animals in the diabetes groups
were excluded (one animal did not develop diabetes after
streptozotocin, two animals died, and four animals were
sacrificed for ethical reasons because of severe weight loss).
2.2. Urinary Albumin Excretion Rate. One week before ter-
mination of the study, the animals were placed individually
in metabolic cages for collection of urine. To lower physical
stress to the animals during isolation, we only collected
urine during a 16 h period from which 24 h urine production
was estimated. Urinary albumin concentrationwasmeasured
by Mouse Albumin ELISA Quantification Kit (Ca E90-134,
Bethyl Laboratories, Inc., Montgomery, TX, USA).
2.3. Samples. Blood samples were drawn to EDTA-coated
tubes (Ca 16.444.100, Sarstedt, Nu¨mbrecht, Germany) at
the start of study before induction of diabetes without
anesthetizing the animals. At the end of study, the animals
were anesthetized by intraperitoneal injection of ketamine
and xylazine (0.5mg/g body weight ketamine, 0.2mg/g body
weight xylazine, both from Intervet, Skovlunde, Denmark).
Blood samples were drawn into EDTA-coated tubes and
placed on wet ice. To avoid ex vivo complement activation
and generation of complement-cleavage product C3a, we
added Futhan immediately after drawing the end-of-study
samples in accordance with manufacture’s instruction (Ca
552035, BD Pharming, Oxford, UK). Plasma was separated
after spin at 4∘C and subsequently frozen to −80∘C.
Dissected kidneys were immediately embedded in
Tissue-Tek optimal cutting temperature (OCT, Ca 62550-01,
ElectronMicroscopy Sciences, Hatfield, PA, USA) and frozen
to −80∘C. Poles of contralateral kidney were snap-frozen in
liquid nitrogen for later RNA isolation.
2.4. Plasma C3 Profile. Circulating C3 concentration was
quantified usingComplement C3Mouse ELISA kit according
to manufacturer’s instructions (Ca ab157711, Abcam, Cam-
bridge, UK).
Circulating C3a concentration was determined by ELISA
as previously described [29]. For capture, we used a rat anti-
mouse antibody with specificity for the neoepitope generated
by the cleavage of C3 and not recognizing intact C3 (Ca
558250, BD Pharming, Oxford, UK). Plates were coated
with antibody diluted to 2𝜇g/mL in borate buffered saline
followed by overnight incubation at 4∘C and subsequently
blocked with sample buffer (PBS, 2% BSA, 0.1% tween-20,
0.02%NaN
3
). Plasma was incubated overnight at 4∘C in sam-
ple buffer. Purified mouse C3a protein was used as standard
(Ca 558618, BD Pharming, Oxford, UK). For detection we
used biotinylated rat anti-mouse C3a antibodies (0.5 𝜇g/mL
in sample buffer, Ca 558251, BD Pharming, Oxford, UK)
which was incubated for 5 h at 4∘C. This was followed
by addition of streptavidin-alkaline phosphatase and later
development with alkaline phosphatase substrate.
2.5. Immunofluorescence. Five-𝜇m thick cryosections were
cut from the OCT embedded kidney blocks and fixed
in acetone. Complement factors were visualized with the
following antibodies: biotinylated rat anti-mouse MBL-C
[30], FITC-conjugated goat anti-mouse C3 (Ca 55500, MP
Biomedicals, Illkirch Cedex, France), FITC-conjugated rat
anti-mouse C4 (Ca CL7504F, Cedarlane, Burlington, NC,
USA), and rabbit anti-rat C9 antibodies cross-reacting with
mouse C9 (gift from B. Paul Morgan, Cardiff University,
UK).Mouse IgGwas stainedwith FITC-conjugated goat anti-
mouse IgG antibody (Ca F5383, Sigma-Aldrich, St. Louis,
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Figure 1: (a) Kidneyweight normalized to bodyweight in control and diabetes group.Within-groupmedian is indicatedwith X.𝑃 value refers
to test statistics from 𝑡-test. (b) Estimated 24 h urinary albumin excretion in control and diabetes group. Within-group median is indicated
with X. 𝑃 value refers to test statistics from 𝑡-test on normally distributed, logarithmic-transformed data.
MO, USA). The biotinylated antibodies against MBL-C were
visualized by streptavidin-conjugated Alexa 488. Rabbit anti-
C9 antibodies were visualized by Alexa Fluor 594-conjugated
F(ab󸀠)2 of goat anti-rabbit IgG polyclonal antibody (Ca
A11072, Life Technologies, Paisley, UK). Complement stain-
ing intensity was quantified in Image Pro Plus software
(MediaCybernetics, Rockville, MD, USA) as the median
immunofluorescence from 10–20 randomglomerular profiles
measured at ×400 magnification using an Olympus BX4
fluorescence microscope (Olympus 6821 Optical, London,
United Kingdom) with a Photonic Science Color Coolview
digital camera attached (Photonic Science, East Sussex, UK)
[31].
2.6. PCR. Glomeruli from snap-frozen kidney poles were
isolated in sterile PBS by the standard sieving technique as
previously described [32]. RNA was extracted by PicoPure
RNA isolation kit (Ca KIT0204). Complementary DNA
was generated by High Capacity cDNA Transcription Kit
(Ca 4368814). Real-time PCR was performed with TagMan
MasterMix (Ca 4364338) containing targetMbl2 primer (Ca
Mm00487623 m1) and housekeeping gene 18S primer (Ca
4319413E) all fromLife Technologies, Paisley, UK. Liver tissue
was used as positive control.
2.7. Statistics. For normally distributed data, the groups were
compared by Student’s 𝑡-test and estimates were expressed
as mean (95% CI). If normal distribution could not be
obtained by transformation of data by natural logarithm,
Wilcoxon rank-sum test was used and the estimates were
expressed as median (interquartile range (IQR)). In graphical
illustration of data, the within-group median is indicated for
all outcomes for consistency. The alpha level for two-sided
tests was set to 5%. As described above, blood glucose con-
centrations above the limit of quantification (33.3mmol/L)
were set to the value 33.4mmol/L used in statistical
evaluation.
3. Results and Discussion
3.1. Results
3.1.1. Blood Glucose and Body Weight. Blood glucose levels
of the animals randomized to the diabetes group and the
control group did not differ before the first streptozotocin
injection (7.1mmol/L [IQR 6.6–7.3] in diabetes group versus
6.8mmol/L [IQR 6.4–7.8] in the control group, 𝑃 = 0.82).
All animals were sacrificed 20 weeks after diabetes was
established. At sacrifice, the diabetes group had significantly
higher blood glucose compared with the control group
(33.4mmol/L [IQR 28.6–33.4] in the diabetes group versus
7.1mmol/L [IQR 6.0–7.9] in the control group, 𝑃 < 0.001).
Animals in the two groups did not differ in body weight
before first streptozotocin injection (24.4 g [95% CI 23.4–
25.3] in the diabetes group versus 24.0 g [95% CI 22.9–25.1]
in the control group, 𝑃 = 0.54). At the end of the study, body
weight of the diabetic animals (21.1 g [95% CI 19.7–22.3]) was
significantly lower than the control animals (35.8 g [95% CI
33.5–38.1]), 𝑃 < 0.001.
3.1.2. Kidney-to-Body Weight Ratio. Kidney weight was nor-
malized to final body weight of the animal to adjust for body
weight differences between the two groups. After 20 weeks of
diabetes, the relative kidney weight was markedly increased,
as expected, in the diabetes group as compared with controls
(Figure 1(a)). The kidney-to-body weight ratio was 9.2mg/g
(95% CI 8.5–9.9) in diabetic mice as compared with 5.6mg/g
(95% CI 5.3–5.9) in age-matched control mice, 𝑃 < 0.001.
3.1.3. Urinary Albumin Excretion (UAE) Rate. No difference
in urinary albumin excretion was found between the groups
(Figure 1(b)). Without reaching statistical significance at the
0.05-level, the diabetic animals had a 1.6-fold (95% CI 0.9–
2.7) higher UAE than control animals, 𝑃 = 0.09.
3.1.4. Glomerulus Immunofluorescence. The staining for
MBL-C was intense in the diabetic animals as opposed to
4 Journal of Diabetes Research
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Figure 2: Illustrative pictures of glomerular staining of complement factors and dot plots of immunofluorescence quantification. Within-
group median of immunofluorescence measurements is indicated with X. (a) Anti-MBL-C stain; 𝑃 value refers to test statistics from 𝑡-test on
normally distributed, logarithmic-transformed data. (b) Anti-C4 stain; NS refers to nonsignificant test statistics in 𝑡-test. (c) Anti-C3 stain;
NS refers to nonsignificant test statistics in 𝑡-test. (d) Anti-C9 stain; NS refers to nonsignificant test statistics in 𝑡-test. (e) Anti-IgG stain; NS
refers to nonsignificant test statistics in 𝑡-test.
almost no staining in controls (Figure 2(a)). The quantified
glomerular MBL fluorescence intensity was 2.0-fold (95%
CI 1.6–2.5) higher in diabetes as compared with control,
𝑃 < 0.001.
We subsequently stained for C4which is deposited (in the
form of C4b) upon complement activation through the lectin
and classical pathway. In both groups, we observed bright
staining but no difference in intensity between the groups,
𝑃 = 0.77 (Figure 2(b)).
Following deposition ofC4b, complement factorC2 binds
to C4b and is transformed to a C3-activating enzyme (by
MBL-associated serine protease-2 in the lectin pathway or by
C1s in the classical pathway), leading to deposition of C3b at
the site of activation.When examining C3 deposition, we did
not find any difference between the two groups, 𝑃 = 0.19
(Figure 2(c)).
The final step of complement attack on a cell surface is the
incorporation of complement factor C9 into the membrane
and formation of the membrane-attack complex (C5b-9).
We did not find any statistical difference in the fluorescence
intensity from anti-C9 antibodies when comparing diabetic
and control animals, 𝑃 = 0.34 (Figure 2(d)).
As control we stained for IgG which did not differ
between the two groups, 𝑃 = 0.23 (Figure 2(e)).
We planned to quantify glomerularMbl2 transcription to
evaluate whether the diabetes-induced increased anti-MBL-
C staining was caused by deposition of circulating MBL
or by increased local MBL production. However, although
the Mbl2 transcript was too low for quantification, the total
RNA yield from isolated glomeruli was very low and we
were therefore unable to make any reliable conclusions from
transcript analysis. The housekeeping gene did give positive
signal in isolated glomeruli. In liver positive controls, we
observed signal from bothMbl2 and housekeeping gene.
3.1.5. Plasma C3 Profile. Total circulating C3 concentra-
tion was determined in plasma samples drawn at sacrifice
(Figure 3(a)). We found the C3 concentration to be signif-
icantly higher in diabetic animals (1375 𝜇g/mL [IQR 1156–
1654]) compared with control animals (651 𝜇g/mL [IQR 532–
719], 𝑃 < 0.001). The concentration did not differ at baseline
(data not shown).
To estimate systemic complement activation, we mea-
sured circulating C3a concentration which is generated when
C3 is cleaved to C3b and C3a and released to circulation.
At the end of the study, the C3a concentration was signifi-
cantly higher in diabetic animals (6.2𝜇g/mL [IQR 4.2–10.0])
Journal of Diabetes Research 5
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Figure 3: Plasma concentration of C3 in control and diabetic group with the within-group median indicated with X. (a) Total C3
concentration; 𝑃 value refers to Wilcoxon rank-sum test. (b) Complement activation product C3a concentration; 𝑃 value refers to Wilcoxon
rank-sum test. (c) Ratio between plasma C3a and total plasma C3; NS refers to nonsignificant Wilcoxon rank-sum test.
compared with controls (3.3 𝜇g/mL [IQR 1.6–8.0]), 𝑃 = 0.04
(Figure 3(b)). No difference between the groups was found at
baseline (data not shown).
As the total C3 concentration was increased in diabetes,
we calculated the ratio between activated C3a and total C3
concentration as measure of relative C3 activation. Even
though the total concentration of activated C3a was higher
in diabetes, the relative C3 activation did not differ between
the two groups as estimated from the C3a-to-C3 ratio
(Figure 3(c), 𝑃 = 0.83).
3.2. Discussion. The present results support our hypoth-
esis as autoreactivity of MBL towards kidney tissue is
increased in diabetes. In addition, we find increased com-
plement activation at systemic level by measurement of
plasma C3a. The proposed mechanism is that prolonged
hyperglycemia in diabetes leads to glycoprotein alterations
which may enable adverse complement activation through
binding of MBL to neoepitopes. However, we were not
able to detect increased complement activation in diabetic
glomeruli, measured as immunofluorescence of C4, C3, or
C9.
High MBL concentration is associated with diabetic
kidney disease in several clinical cohorts [4–9]. A causal role
of MBL in diabetic kidney disease is indicated in animal
studies showing that MBL deficiency attenuates diabetes-
induced kidney changes, but the underlying mechanisms
have not been identified [11, 12].
MBL is a pattern-recognitionmolecule that binds specific
carbohydrate patterns [33]. These carbohydrate patterns are
commonly found on yeast and bacteria in sufficient density
to allow high-avidity binding of multiple subunits in the
MBL polymer. Normally, MBL does not activate complement
in healthy tissue as normal human glycoproteins are not
recognized with a sufficiently high binding strength. Further-
more, a large number of complement-regulating proteins in
circulation and on cell surfaces minimize complement self-
attack in humans. In addition to the antimicrobial activity,
MBL also plays a role in tissue homeostasis, for example, by
opsonizing apoptotic cells [34, 35].
A proposed mechanism is hyperglycemia-driven alter-
ations in carbohydrate patterns that enable MBL-mediated
adverse complement self-attack in diabetes [6, 13]. In vitro
studies suggest that MBL is able to recognize advanced gly-
cation end-products and activate complement, but whether
this resembles in vivo conditions is not known [13, 14].
The present study therefore aimed to investigate three
questions: firstly, if MBL autoreactivity is increased within
the diabetic glomerulus; secondly, if glomerular complement
activation is increased; and thirdly, if diabetes increases the
degree of complement activation at systemic level.
The present study shows that diabetic animals have a
more intense glomerular staining for MBL as compared with
nondiabetic controls. As the local Mbl2 transcription was
below the limit of quantification, we conclude that the MBL
staining arises from MBL deposition from the circulating
pool. These results point towards a direct effect of MBL in
diabetic kidney disease.
The next question we asked was if the increased MBL
deposition would translate into an increased staining for the
downstream complement components. These complement
components are gradually deposited on the target during
successive steps of complement factor cleavages.We therefore
stained for C4, C3, and C9 in order to detect complement
activation within the kidney.
We found positive staining for all the downstream
complement factors, but we were not able to detect any
differences between the diabetic andnondiabetic groups.This
might be explained by insufficient sensitivity to detect small
differences by immunofluorescence. Diabetes complications
in the kidney normally develop slowly over a long time
span, and even very small degrees of complement activation,
undetectable by immunofluorescence, may eventually lead to
an accelerated development of kidney disease. Immunoflu-
orescence as method thus limits the ability of our study to
detect subtle differences in complement activation that might
prove to be of physiological relevance. As complement is
6 Journal of Diabetes Research
activated ex vivo as function of time and temperature, it is
not possible to use existing human samples collected without
control of complement for post hoc evaluation of diabetes-
induced complement activation [36]. Thirdly, we measured
complement activation at the systemic level by quantifying
the cleavage product C3a in plasma in an assay not recog-
nizing the nonactivated intact C3. Plasma samples from the
end of the study were collected with admixture of an enzyme
inhibitor and rigorous control to avoid spontaneous ex vivo
complement activation [36].We found that diabetic mice had
increased C3a concentrations as compared with control mice
indicating a higher degree of complement activation. The
plasma concentration of total C3 (including nonactivated C3)
was also increased in diabetes. While C3 is predominantly
produced in the liver, C3 has been reported to be transcribed
and translated at a higher level within glomeruli of patients
with diabetic kidney disease as compared with healthy
controls [37]. Low RNA yield in sieve-isolation of glomeruli
prevents our study from similar assessments. Although total
C3 and activated C3a were measured in two different assays
on different standard curves, we calculated the relative C3
activation as the ratio between C3a and total C3 concen-
trations. From this ratio we find that while the absolute
complement activationmeasured by circulating C3a is higher
in diabetes, the relative activation did not differ between
groups.
4. Conclusions
In conclusion, the present study shows that diabetes leads
to MBL deposition within the glomerulus and a higher
plasma concentration of the complement activation product
C3a. This indicates that the previously described role of
MBL in diabetic kidney disease can be explained by MBL’s
recognition of hyperglycemia-induced neoepitopes in the
diabetic glomerulus. From the increase in circulating C3a
concentration in diabetes, it is reasonable to speculate that
complementmay also be activated outside the kidney atmore
abundant sites, for example, the vascular wall. However, this
needs to be investigated in future studies.
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